"id:ID","id","studyRationale","studyVersion","uuid","studyTitle","studyAcronym"
"821","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","bdd30cc0-fe5b-470d-857c-8ef891327469","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","H2Q-MC-LZZT"
